Clinical Trials Browser

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT03410693 2022-09-28

FORT-1

Phase 2/3 Completed

175 enrolled 19 charts

Genitourinary

Carcinoma, Transitional Cell

NCT05429515 2022-06-23

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Phase 4 Not yet recruiting

50 enrolled

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT00004026 2020-10-19

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Phase 2 Terminated

80 enrolled

Genitourinary

Prostatic Neoplasms

NCT04588168 2020-10-19

Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma

Phase NA Recruiting

100 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT01993979 2020-05-04

POUT

Phase 3 Unknown

261 enrolled

Genitourinary

Transitional Cell Carcinoma of Ureter

NCT01094496 2020-02-13

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Phase 2 Terminated

3 enrolled

Genitourinary

Urinary Bladder Neoplasms, Urogenital Neoplasms

NCT00002677 2019-11-04

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

Phase 1 Completed

24 enrolled

Genitourinary

Prostatic Neoplasms

NCT01811810 2019-04-23

Proton Therapy for High Risk Prostate Cancer

Phase NA Withdrawn

Genitourinary

Prostatic Neoplasms

NCT03524391 2018-05-14

Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients

Phase NA Completed

92 enrolled

Genitourinary

Prostatic Neoplasms

NCT00006376 2013-12-04

R115777 in Treating Patients With Advanced Bladder Cancer

Phase 2 Completed

Genitourinary

Urinary Bladder Neoplasms

NCT00005848 2013-07-11

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

7 enrolled

Genitourinary

Prostatic Neoplasms

NCT00002737 2012-07-11

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Phase 3 Completed

320 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00283062 2012-01-26

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Phase 3 Completed

228 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT00179816 2010-10-11

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

Phase 1/2 Unknown

12 enrolled

GastrointestinalGenitourinaryLymphoidSarcoma

Hodgkin Disease, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Sarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT00089856 2008-11-05

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 3 Terminated

626 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00133224 2008-09-23

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Phase 3 Terminated

408 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00108290 2008-04-04

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

Phase 2 Completed

Genitourinary

Prostatic Neoplasms

Clinical Trials

TroFuse-031

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

g-RAMPP

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

MESODEC

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

3 Tesla MRI in Patients With Bladder Cancer

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer

A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

FORT-1

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma

POUT

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

Proton Therapy for High Risk Prostate Cancer

Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients

R115777 in Treating Patients With Advanced Bladder Cancer

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer